MedDataX Logo

Effect of Intravitreal Bevacizumab on Corneal Endothelium

NCT ID: NCT01726790

Last Updated: 2012-11-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

37 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corneal Endothelial Cell Loss

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

corneal endothelium Bevacizumab Intravitreal injection Confoscan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged between 20 and 80 years old
* can come to regular follow up at 6 month
* signed written consent forms
* not have corneal scar, or glaucoma
* history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit
* high risk in cerebrovascular and cardiovascular diseases
* Pregnancy and breastfeeding
* can undergo confocal microspopy

Exclusion Criteria

* History of intraocular surgery or ocular trauma during study
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Khon Kaen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kasem Yospaiboon

Kasem Yospaiboon, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KKU eye center, department of Ophthalmolgy, faculty of medicine, khon kaen university

Khon Kaen, Changwat Khon Kaen, Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kasem Yospaiboon, MD

Role: CONTACT

Phone: 66823057231

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yosanan Yospaiboon, Professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HE541020

Identifier Type: -

Identifier Source: org_study_id